Wave Life Sciences Ltd (NASDAQ:WVE) insider Michael A. Panzara sold 3,058 shares of Wave Life Sciences stock in a transaction on Friday, July 5th. The stock was sold at an average price of $26.94, for a total value of $82,382.52. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
WVE stock opened at $26.26 on Thursday. The stock has a market cap of $899.80 million, a P/E ratio of -5.19 and a beta of 0.83. Wave Life Sciences Ltd has a 1 year low of $22.25 and a 1 year high of $56.00. The company has a current ratio of 2.39, a quick ratio of 2.39 and a debt-to-equity ratio of 0.16. The business has a fifty day moving average price of $25.38.
Wave Life Sciences (NASDAQ:WVE) last released its quarterly earnings results on Friday, May 10th. The company reported ($1.36) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.19) by ($0.17). The firm had revenue of $3.03 million during the quarter, compared to analysts’ expectations of $9.66 million. Wave Life Sciences had a negative return on equity of 120.60% and a negative net margin of 971.48%. Sell-side analysts expect that Wave Life Sciences Ltd will post -4.23 earnings per share for the current year.
Hedge funds have recently added to or reduced their stakes in the company. Citigroup Inc. boosted its stake in shares of Wave Life Sciences by 189.4% in the 4th quarter. Citigroup Inc. now owns 2,807 shares of the company’s stock worth $118,000 after buying an additional 1,837 shares during the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. boosted its stake in shares of Wave Life Sciences by 17.9% in the 1st quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 3,045 shares of the company’s stock worth $118,000 after buying an additional 462 shares during the last quarter. Amundi Pioneer Asset Management Inc. boosted its stake in shares of Wave Life Sciences by 45.0% in the 4th quarter. Amundi Pioneer Asset Management Inc. now owns 2,900 shares of the company’s stock worth $122,000 after buying an additional 900 shares during the last quarter. Legal & General Group Plc boosted its stake in shares of Wave Life Sciences by 17.9% in the 4th quarter. Legal & General Group Plc now owns 3,094 shares of the company’s stock worth $130,000 after buying an additional 469 shares during the last quarter. Finally, SG Americas Securities LLC purchased a new position in shares of Wave Life Sciences in the 1st quarter worth $140,000. Hedge funds and other institutional investors own 85.62% of the company’s stock.
About Wave Life Sciences
Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces of novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. The company is primarily developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins.
Further Reading: What economic reports are most valuable to investors?
Receive News & Ratings for Wave Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Wave Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.